Exposure to traffic-related air pollution and bacterial diversity in the lower respiratory tract of children

Christine Niemeier-Walsh\textsuperscript{1}, Patrick H. Ryan\textsuperscript{1,2,3}, Jaroslaw Meller\textsuperscript{1,2}, Nicholas J. Ollberding\textsuperscript{2,3}, Atin Adhikari\textsuperscript{4}, Tiina Reponen\textsuperscript{1*}

\textsuperscript{1} Department of Environmental Health, University of Cincinnati, Cincinnati, OH, United States of America, \textsuperscript{2} Department of Pediatrics, University of Cincinnati, Cincinnati, OH, United States of America, \textsuperscript{3} Division of Biostatistics and Epidemiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States of America, \textsuperscript{4} Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, Georgia, United States of America

\textsuperscript{*} Tiina.Reponen@uc.edu

Abstract

Background

Exposure to particulate matter has been shown to increase the adhesion of bacteria to human airway epithelial cells. However, the impact of traffic-related air pollution (TRAP) on the respiratory microbiome is unknown.

Methods

Forty children were recruited through the Cincinnati Childhood Allergy and Air Pollution Study, a longitudinal cohort followed from birth through early adolescence. Saliva and induced sputum were collected at age 14 years. Exposure to TRAP was characterized from birth through the time of sample collection using a previously validated land-use regression model. Sequencing of the bacterial 16S and ITS fungal rRNA genes was performed on sputum and saliva samples. The relative abundance of bacterial taxa and diversity indices were compared in children with exposure to high and low TRAP. We also used multiple linear regression to assess the effect of TRAP exposure, gender, asthma status, and socioeconomic status on the alpha diversity of bacteria in sputum.

Results

We observed higher bacterial alpha diversity indices in sputum than in saliva. The diversity indices for bacteria were greater in the high TRAP exposure group than the low exposure group. These differences remained after adjusting for asthma status, gender, and mother’s education. No differences were observed in the fungal microbiome between TRAP exposure groups.
Conclusion

Our findings indicate that exposure to TRAP in early childhood and adolescence may be associated with greater bacterial diversity in the lower respiratory tract. Asthma status does not appear to confound the observed differences in diversity. These results demonstrate that there may be a TRAP-exposure related change in the lower respiratory microbiota that is independent of asthma status.

Introduction

For many years it was believed that the lungs were sterile due to the limitation of characterizing bacterial communities through culture-dependent methods [1]. However, with the advancement of molecular-based microbial identification techniques, numerous studies have confirmed that the lungs, do in fact, contain bacterial communities [2–7], and that the microbial community composition may play a role in the exacerbation of chronic lung disease [8].

Traffic-related air pollution (TRAP) has been associated with exacerbation of existing asthma and incident asthma among young and adolescent children [9–19]. TRAP exposure has also been associated with a heightened risk of bacterial pneumonia in older adults and adults with chronic obstructive pulmonary disease (COPD) [20,21]. The mechanism responsible for this association is unclear. Aggregates of elemental carbon nanoparticles are common components of urban PM [22,23] and are retained by lung tissue [22]. They have the capacity to induce pulmonary oxidative stress [24] and to stimulate proinflammatory cytokine release from airway cells [25]. It is noteworthy that TRAP can increase adherence of microorganisms to the epithelial cells of the respiratory tract [26], damaging cells in epithelial layers of the respiratory tract [25], which may cause increased susceptibility to microbial growth. A role for microbiota in the etiology of asthma has been suggested [27]. However, the relationship between the bacterial flora in the respiratory tract and allergic immune responses and asthma is not well understood. Airways of asthmatics contain a characteristic microbial flora [28], and neonatal colonization of the upper airway with some bacteria (e.g., Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis) during infancy increases the risk for recurrent and severe wheezing and asthma [29]. The airway microbiota may interact with the innate and adaptive arms of the host’s mucosal immune system in the respiratory tract (e.g., by activating tolerogenic dendritic cells) and influence regulatory T and B cell induction and differentiation in the lung and respiratory tract. Thus, this interaction can be critically important in maintaining immune tolerance. Conversely, epidemiologic studies have consistently indicated that a rich microbial environment in early life provides protection against the development of asthma [30–32].

Exposure to particulate matter (PM) increases the adhesion of bacteria to human airway epithelial cells and PM-stimulated adhesion is mediated by oxidative stress and the receptor for platelet-activating factors [26]. As described above, exposure to TRAP is associated with incident and exacerbation of existing asthma [9–19]. However, the component of TRAP responsible for this association has not been identified. Previous studies indicate that carbonaceous PM may have a major role in adverse health effects [33–36]. Ultrafine particles dominate particle number concentrations in outdoor urban air, and carbon particles are a major component of these. These ultrafine particles can agglomerate, be retained by the lung tissue upon inhalation [22–25]. There is also evidence that PM promotes airway bacterial infection by weakening the production of an antimicrobial peptide, β-defensin-2 [37]. Several
epidemiological studies have documented an association between pneumonia and urban PM [20,21,38]. Additionally, both the bacterial load and diversity were found to be greater for asthmatic than non-asthmatic adult participants using high-throughput sequencing of sputum samples [39,40]. Therefore, it is possible that chronic exposure to TRAP may increase the adhesion of microorganisms to the respiratory tract, altering the microbiome of the respiratory tract over time. Microbiome dysbiosis in the respiratory tract may destabilize homeostatic balance between host and microorganism, and changes the physiological environment of airways and accumulation of toxic metabolites there leading to the outgrowth of pathogenic bacteria [41,42]. This can develop inflammation and the damage of epithelial barrier and lung tissues through the production of reactive oxygen species (ROS). The role of ROS in allergic asthma has been established in many previous studies [43]. Thus, characterization of the extent, nature, and function of microbial flora in the airways and its interplay with environmental exposures—including TRAP—is essential to understand the etiology of respiratory allergy and asthma.

Although recent studies have examined the association of TRAP exposure and the gut microbiome, to our knowledge, there have been no reports on the effects of TRAP on the human respiratory tract microbiome, particularly among children [42,44–47]. The gut and the lungs are connected via a common mucosal response, as lymphoid cells can travel between mucosal membranes and cause an inflammatory response in multiple areas of the body [48–50]. Therefore, it is plausible that the gut and respiratory system are impacted simultaneously by TRAP exposure.

The main focus of this pilot study was to explore the association between childhood exposure to TRAP and the microflora in the lower respiratory tract of children. Asthma status was included as a potential confounding variable as previous studies have shown differences between respiratory microbiome between asthmatics and non-asthmatics. The participants were recruited from a longitudinal cohort, followed from birth through early adolescence, with a well-characterized TRAP exposure history.

Methods
Recruitment

We recruited adolescents enrolled in the Cincinnati Childhood Allergy and Air Pollution Study (CCAAPS) cohort to participate in this study [51]. Briefly, children were enrolled in CCAAPS prior to age one and longitudinally evaluated for allergy and asthma development at clinic visits at ages 1, 2, 3, 4, 7, and 12. Clinic visits included skin prick tests to 15 aeroallergens, spirometry, and questionnaires to assess address history for home, daycare and school, tobacco smoke exposure, pet ownership, home characteristics, and respiratory health [52–56]. At age 12, asthma status was determined by parent report of a physician diagnosis of asthma. Exclusion criteria for this study included having exposure to environmental tobacco smoke at either age 12 CCAAPS clinic visit or at the time of sputum sampling (~ 14 y), or having an upper or lower respiratory infection within 4-weeks prior to sputum sampling, following the protocol by Tunney et al. [57]. We also collected sputum and saliva samples from four pilot participants prior to recruiting the forty full study participants to confirm that we would be able to obtain a sufficient amount of sputum and bacterial DNA from the healthy adolescent population. The study protocol was approved by the University of Cincinnati Institutional Review Board and informed parental consent and participant assent were obtained prior to study participation.

Our primary hypothesis was that there is a significant difference in microbial richness in the respiratory tract of children exposure to low versus high TRAP. Since there were no previously published data on the effects of TRAP on the microbial richness in the respiratory tract
of asthmatic children, we based our sample size calculations on estimates reported by Hilty et al. [28]. Means and standard deviations for microbial richness in asthmatic samples were obtained through personal communication with the author and served as estimates for the low TRAP exposed samples. For alpha = 0.05 (two-sided), n = 18 low TRAP and n = 18 high TRAP samples provide 80% power (1 –beta) to detect a difference in microbial richness as small as five observed ASVs for the Wilcoxon rank-sum test when the actual data distribution is normal, and the SD is 5.0 in both groups. Power exceeds 70% with as few as n = 15 in each group. We recruited a total of 40 subjects to account for potential subject drop-out and non-amplifiable samples.

**TRAP exposure estimation**

A land-use regression (LUR) model to estimate exposure to a surrogate of TRAP, elemental carbon attributable to traffic (ECAT), has been developed, refined, and validated as part of the CCAAPS [58,59]. Briefly, an ambient air sampling network, consisting of 27 sites, was operated from 2001–2006 [38], and samples were analyzed for PM2.5 mass concentrations, 39 elements, and elemental and organic carbon [60]. A multivariate receptor model, UNMIX, was used to determine significant sources contributing to PM2.5, including traffic. The contribution to PM2.5 from diesel traffic was assessed using elemental source profiles identified from measurements conducted at cluster sources of trucks and buses [60]. A marker of traffic-related particles specifically related to diesel combustion, the ECAT, was derived for each sampling site and served as the dependent variable for the LUR model. Significant predictor variables in the LUR model included elevation and nearby truck traffic and bus routes [58,60,61]. A time-weighted average (TWA) daily exposure of ECAT was calculated for each age of children taking into account the locations where they spent more than eight hours per week, up until age 12, where only the home address was used. For this study, we categorized participants as exposed to high or low levels of TRAP if their average exposure from birth through age 12 was above or below the median exposure of all participants who completed the age 12 study visit.

**Sample collection and preparation**

Saliva samples and induced sputum samples were collected at one time point at participants’ age of ~14 years with the assistance of the Schubert Research Clinic at Cincinnati Children’s Hospital Medical Center. Immediately prior to sputum induction, participants rinsed their mouths with nuclease-free water, and then 2 mL of saliva was collected using the Norgen Saliva DNA Collection Kit (Norgen BioTek Corp., Thorold, ON, Canada) according to the manufacturer’s instructions. Saliva was collected first so that we could compare the bacterial communities in saliva to those in sputum to ensure that the bacterial communities were distinct and that the sputum samples were not entirely contaminated by the oral microbiome. Next, participants underwent a spirometry assessment and received a dose of albuterol. To induce sputum production, participants breathed in a nebulized hypertonic saline solution for five minutes, then coughed the sputum into a Norgen Sputum DNA Collection Kit (Norgen BioTek Corp., Thorold, ON, Canada). This cycle was repeated up to five times, or until 2 mL of sputum had been collected. After adding the Norgen Collection Kit preservative, which preserves the samples for up to five years at room temperature, sputum and saliva samples were stored at room temperature until DNA extraction.

**DNA isolation**

DNA from saliva was extracted using the Norgen Saliva DNA Isolation Kit (Norgen BioTek Corp., Thorold, ON, Canada). DNA from sputum was extracted using the Norgen Sputum
DNA Isolation Kit (Norgen BioTek Corp., Thorold, ON, Canada). Sputum was first liquefied using a 100 μg/mL solution of dithiothreitol and incubated at 37˚C for 60 minutes. The manufacturer’s protocol was used for DNA isolation of sputum and saliva samples, with one modification: after adding the protein kinase K and lysozyme, the sample was incubated in an ultrasonic water bath at 65˚C for 30 minutes. This modification was made based on recommendations by Luhung et al. [62] for protocol improvements for DNA isolation of biological aerosol samples with low concentrations of DNA, as we expected low DNA yield from these samples based on our pilot samples.

Real-Time Quantitative-PCR (qPCR)

To measure the total bacterial DNA present in the samples, the universal primers, UniBacteria_F and UniBacteria_R, and probe, UniBacteria_P1, for the amplification of the 16s bacterial rDNA were used as described by Nadkarni et al. [63]. Extracted DNA from a solution of Bacillus atrophaeus with a known concentration of cells was used as the standard. Fungal qPCR methods are described by Haugland and Vesper [64] and included in the supplemental information. A set of PCR reaction mixtures were spiked with a known concentration of DNA to test for inhibition. A serial dilution was also included in the well plate as an internal standard to check for pipetting errors. Amplification was performed using the TaqMan system on Applied Biosystems StepOnePlus Real-Time PCR System. All qPCR reactions were replicated three times per sample, and the reported value is the mean of the triplicates. Reagent blanks were also included.

Metagenomics sequencing

For bacterial sequencing, we chose to amplify the V4 region of 16s bacterial rDNA (primer set 515F-806R) with v2 chemistry because these conditions have documented lower error rates [65,66]. PCR was carried out by adding 3.5 μL of each forward and reverse primer and 4 μL of Master Mix, containing 0.3 μL 10 mM dNTP, 1.5 μL buffer + MgCl₂, 0.1 μL FastStart Taq DNA Polymerase, and 2.1 μL nuclease-free water, to 4 μL of DNA extract of each sample. The following thermocycling conditions were used for amplification: 94˚C for 60 seconds, 30 cycles of 94˚C for 30 seconds, 50˚C for 45 seconds, and 72˚C for 120 seconds, then 72˚C for 300 seconds, and lastly, a 10˚C hold. Paired-end sequencing (250 x 2) was performed on the Illumina MiSeq (Illumina Inc., San Diego, CA). PCR amplification and sequencing were performed by the Cincinnati Children’s Hospital and Medical Center DNA Core. Fungal sequencing methods are included in the supplemental information.

Primer sequences were removed using cutadapt v1.16 [67]. The open-source R package, DADA2 v1.8, was used to process reads and for error correction [68]. The default parameters were used for quality filtering, error modeling, dereplication, denoising, and merging of paired-end reads. For bacteria, forward reads were truncated at 210 and reverse reads were truncated at 160 nucleotides. Reads with a quality score less than or equal to two, with a maximum expected error rate for the forward or reverse read greater than two, or with a forward or reverse read that contained an ambiguous base were removed. After error correction, the forward and reverse reads were merged to form an amplicon sequence variant (ASV) table. The DADA2 function removeBimeraDenovo was used for chimera removal. Silva version 132 was used as the reference database for bacterial taxonomic classification [69]. Sequences were aligned using the AlignSeqs function in the DECIPHER package v2.12.0 [70]. For bacteria, a de novo phylogenetic tree was generated using the phangorn package v2.5.5 [71]. Phyloseq v1.28 was used to integrate the sample metadata, ASV table, phylogenetic tree, and taxonomic assignments for statistical analyses [72]. This method was selected over the construction of
operational taxonomic units (OTUs) as it has been argued that using ASVs as the unit for marker-gene analysis improves reusability, reproducibility, and comprehensiveness of data [73]. Fungal metagenomics sequencing methods are described in the supplemental information.

Data analysis
We accounted for differences in sequencing depth by multiplying the relative abundance values by the qPCR values for each sample to calculate absolute abundance [74,75]. Two sputum samples were removed from the bacterial dataset due to a low number of reads (<5000 total reads). Four other sputum samples and four saliva samples were not included in the bacterial dataset because the rDNA did not amplify either during qPCR or during PCR amplification prior to 16s sequencing. Four saliva samples were not included in the bacterial dataset because the rDNA did not amplify during qPCR or during PCR amplification prior to 16s sequencing. The number of observed ASVs and Shannon alpha diversity were calculated using phyloseq::estimate_richness and Faith’s phylogenetic diversity was calculated using the function pd in the picante R package (v1.8.0) [76].

Alpha diversity indices between sample types, between exposure groups, between genders, and between asthma status groups were first univariately compared using the Wilcoxon rank sum test. We used multiple linear regression to model the effect of TRAP, adjusted for gender, asthma status, and mother’s education as a measure of socioeconomic status, on the alpha diversity in sputum. TRAP exposure was modeled both as a categorical (high/low) and continuous (ECAT) variable (high/low) in separate models. The overall bacterial abundance from qPCR was compared between TRAP exposure groups, asthma status groups, and genders using the Wilcoxon rank sum test.

The Adonis function in the vegan package (2.5–6) was used to implement a permutational multivariate analysis of variance to test for differences in beta diversity between sample types. A dispersion test for the homogeneity of variance across sample type was also conducted using the vegan::betadisper and vegan::permutest functions, as differences in variance may confound the Adonis test. Negative binomial regression as implemented by DESeq2 (version 1.24.0) was used to estimate the fold-change of taxa in sputum according to asthma status, gender, and TRAP exposure groups [77]. Taxa that were not observed in at least 20% of samples were excluded from the DESeq2 analyses. The Human Microbiome Project (HMP) R package (v.2.0.1) function xdc.sevsample was used to assess the distribution of major phyla between sample type, and in sputum samples, between asthma status, gender, and TRAP exposure groups [78].

Results
Characteristics of study participants
Sputum samples from 34 of the participants were included in the bacterial analyses. There were 17 participants in each TRAP exposure group for bacteria. The median ECAT in the high exposure group was 0.46 μg/m³, and the median ECAT in the low exposure group was 0.29 μg/m³. The cut-off between the low and high exposure groups was ECAT = 0.33 μg/m³. In the high exposure group, 42% of the participants were female, 35% were asthmatic, and 82% of the mothers had education beyond high school. In the low exposure group, 53% were female, 18% were asthmatic, and 100% of the mothers had education beyond high school.

Saliva samples from 36 participants were included in the bacterial analyses. For saliva samples, there were 16 participants in the low exposure group and 20 participants in the high exposure group. Of the saliva samples included in the high exposure group, 50% of participants
were female, 35% were asthmatic, and 85% of the mothers had education beyond high school. Of the saliva samples included in the low exposure group, 50% participants were female, 13% were asthmatic, and 100% of the mothers had education beyond high school.

Fungal abundance was low in sputum and saliva samples. We were able to include 10 sputum and 8 saliva samples in the fungal analyses. Therefore, the fungal data, including the characteristics of participants for fungi, are described in the supplemental information.

**Distinction between sputum and saliva**

Sputum had a greater median bacterial alpha diversity than saliva for all three diversity measures (Fig 1). The median Shannon diversity index was 3.7 in sputum and 3.4 in saliva (p<0.001). The number of observed ASVs was 168 in sputum and 157 in saliva (p = 0.019). The median phylogenetic diversity index was 8.3 in sputum and 7.7 in saliva (p = 0.6).

The most abundant bacterial phyla in both sputum and saliva samples were **Actinobacteria**, **Firmicutes**, **Bacteroidetes**, and **Proteobacteria**. All other less abundant phyla were combined into one “other” category for testing the distribution of the phyla between sputum and saliva. The results indicated that the distribution of phyla differed in sputum and saliva (p≤0.001). **Actinobacteria** and **Firmicutes** were more abundant in sputum and **Proteobacteria** and **Bacteroidetes** were more abundant in saliva (S1 Fig).

We used the Bray-Curtis dissimilarity metric to compare the microbial community composition between the two sample types for bacteria (Fig 2). The Adonis test indicated that 6% of

---

**Sample Type**

Fig 1. Box plots comparing bacterial alpha diversity indices between sputum and saliva, including Shannon diversity, number of observed amplicon sequence variants (ASVs), and Faith’s phylogenetic diversity.

https://doi.org/10.1371/journal.pone.0244341.g001
the variance in the distance matrix between sputum and saliva could be attributed to the sample type (p = 0.001). The homogeneity of dispersion test failed to reject the null hypothesis that the variances of the sputum and saliva samples were similar (p = 0.31) indicating no confounding effect for a difference in variance; however, several outlying saliva samples were observed. We also examined the beta diversity between sputum and saliva using the unweighted UniFrac and Jaccard methods to assess the robustness of the findings to the chosen distance/dissimilarity measure and approach (S2 Fig).

### Bacterial microbiota differences in TRAP exposure groups

**Alpha diversity.** There was greater diversity in the sputum of the high TRAP exposure group when compared to the low exposure group (Fig 3). Univariate analysis showed that the number of observed ASVs, Shannon diversity, and Faith’s phylogenetic diversity were all greater in the high TRAP exposure group for bacteria (Table 1). For phylogenetic diversity, there was also a statistically significant difference between genders (Table 1, S3 Fig). There was noticeable within-group variability, suggesting other unidentified factors may be impacting alpha-diversity estimates. There were no statistically significant differences between asthma status groups (Table 1, S3 Fig). In contrast to sputum, there were no observed differences in bacterial alpha diversity in saliva between TRAP exposure group, gender, nor asthma status (S4 Fig).

Using multiple linear regression, TRAP, both as a categorical (high/low) and continuous (ECAT) variable, was positively associated with an increased number of observed ASVs and
phylogenetic diversity after adjusting for asthma status, gender and mother’s education (Table 2). TRAP as a categorical variable was positively associated also with Shannon diversity. Female gender was positively associated with the number of observed ASVs and phylogenetic diversity, but not with Shannon diversity. Neither asthma status nor mother’s education were statistically significant predictors of alpha diversity indices.

**Beta diversity.** The Bray-Curtis dissimilarity measure figures did not show a distinction in bacterial microbiota in sputum between TRAP exposure group, asthma status group, or gender (Fig 4). However, the Adonis test indicated that 6% of the variance in the distance matrix between

### Table 1. Mean (95% confidence interval) and p-value for each bacterial alpha diversity measure in the sputum by TRAP exposure, asthma status, and gender.

|                          | TRAP Exposure | Asthma Status | Gender |
|--------------------------|---------------|---------------|--------|
|                          | High (n = 17) | Low (n = 17)  | p-value | Asthmatic (n = 9) | Non-Asthmatic (n = 25) | p-value | Female (n = 16) | Male (n = 18) | p-value |
| **Number of Observed ASVs** | 191 (168–214) | 149 (133–164) | p = 0.008** | 179 (154–204) | 166 (147–185) | p = 0.38 | 184 (158–210) | 157 (141–173) | p = 0.06 |
| **Shannon Diversity**    | 3.8 (3.7–3.9) | 3.5 (3.3–3.7) | p = 0.05*  | 3.7 (3.6–3.8) | 3.6 (3.4–3.7) | p = 0.51 | 3.7 (3.5–3.9) | 3.6 (3.5–3.7) | p = 0.16 |
| **Phylogenetic Diversity** | 9.2 (8.5–9.9) | 7.7 (7.1–8.3) | p = 0.002** | 8.6 (7.6–9.6) | 8.4 (7.8–9.0) | p = 0.51 | 9.0 (8.2–9.8) | 7.9 (7.3–8.5) | p = 0.04* |

Wilcoxon rank sum test; Significance levels
* = \( p \leq 0.05 \)
** = \( p \leq 0.01 \).

https://doi.org/10.1371/journal.pone.0244341.t001
the sputum of asthmatics and non-asthmatics could be attributed to asthma status (p = 0.04). The Adonis test also indicated that 6% of the variance in the distance matrix between the sputum of male and female participants could be attributed to gender (p = 0.04). The homogeneity of dispersion test showed no significant difference in the variances of the sputum samples from each asthma status group (p = 0.88) or from each gender (p = 0.46) indicating no confounding effect from a difference in variances. The Adonis test did not indicate that the variance in sputum between TRAP exposure groups could be attributed to TRAP exposure (p = 0.9).

Relative abundance. According to the xdc.sevsample test, the distribution of major phyla did not differ in sputum between each TRAP exposure group nor each gender (p = 0.43 and p = 1.0, respectively). However, a significant difference in major phyla was found between asthma status groups (p ≤ 0.001). These results are in agreement with the relative abundance bar plots (Figs 5 and S5). The relative abundance of phyla in sputum does not appear to differ between TRAP exposure group nor gender, but asthmatics appear to have more Bacteroidetes and fewer Proteobacteria.

Differential abundance. While the overall microbial community composition did not appear to differ between TRAP exposure groups, negative binomial regression was able to identify several individual ASVs with a log2 fold-change greater than 2 and FDR p ≤ 0.05 according to TRAP exposure groups (high vs. low) (Fig 6). Fusobacterium nucleatum had a log2 fold change of 25 (FDR p ≤ 0.001). Two other ASVs in the Fusobacterium genus had FDR p-values ≤ 0.001, with log2 fold-changes of 24 and 9, and one ASV in the genus Atopobium (family Atopobiaceae) had a log2 fold-change of 7 (FDR p = 0.02) across the TRAP exposure groups. While the FDR p-values for the ASVs in the family Prevotellaceae were not < 0.05, the log2 fold-changes were more consistently > 2 for individual ASVs in the family.
Fig 4. Non-metric multidimensional scaling (NMDS) of Bray-Curtis distances of bacteria in sputum microbiota from each TRAP exposure group, asthma status group, and gender.

https://doi.org/10.1371/journal.pone.0244341.g004

Fig 5. Bar plots showing the relative abundance of bacterial phyla in sputum across (A) TRAP exposure groups, (B) asthma status groups, and (C) genders.

https://doi.org/10.1371/journal.pone.0244341.g005
We also identified several ASVs that were differentially abundant in sputum across gender (female vs. male) and two ASVs that were differentially abundant in sputum across asthma status groups (asthmatic vs. non-asthmatic) (S6 and S7 Figs). Across gender, there were two ASVs in *Fusobacterium* with log2 fold-changes of 24 and 25 (FDR p < 0.001), one ASV in the genus *Campylobacter* (family *Campylobacteraceae*) with a log2 fold-change of -8 (FDR p = 0.01), and one ASV in the genus *Prevotella* (family *Prevotellaceae*) with a log2 fold-change of -7 (FDR p = 0.03). Across asthma status, there was one ASV identified as *Prevotella salivae* with a log2 fold-change of -3 (FDR p = 0.008), and one ASV in the genus *Bacillus* (family *Bacillaceae*) with a log2 fold-change of 8 (FDR p = 0.05).

**Overall bacterial load**

We compared the overall bacterial load in sputum, as measured by qPCR with universal bacterial primers, between TRAP exposure groups, between asthmatics and non-asthmatics, and between genders using Wilcoxon rank sum test. No significant difference in the overall bacterial load was observed.
bacterial load was observed between high and low TRAP exposure groups (median high TRAP = 6.9 x 10^5 bacterial genome copies per mL of sputum, median low TRAP = 3.6 x 10^5 bacterial genome copies per mL of sputum; p = 0.43) (Fig 7). However, there was a higher bacterial load in the sputum of asthmatic participants than in non-asthmatic participants (median asthmatic = 1.3 x 10^6 bacterial genome copies per mL of sputum, median non-asthmatic = 3.6 x 10^5 bacterial genome copies per mL of sputum; p = 0.07) and in the sputum of male than in female participants (median male = 9.4 x 10^5 bacterial genome copies per mL of sputum, median female = 1.7 x 10^5 bacterial genome copies per mL of sputum; p = 0.006) (Fig 7). We also found a higher bacterial load in the saliva of asthmatics (median asthmatic = 4.0 x 10^6 10^5 bacterial genome copies per mL of saliva, median non-asthmatic = 1.3 x 10^6 10^5 bacterial genome copies per mL of saliva; p = 0.05). There were no differences in the bacterial load in saliva between TRAP exposure groups (p = 0.26) nor between genders (p = 0.65).

Traffic pollution and the respiratory fungal microbiota (mycobiome)

We compared the sputum mycobiome of high and low TRAP-exposed participants, as well as by gender and asthma status. We did not observed any significant differences in alpha diversity when comparing TRAP exposure groups, genders, and asthma status groups (S1 Table). There also were no significant differences in beta diversity (Bray-Curtis) between asthma status groups, TRAP exposure groups, nor between genders. It should be noted, however, that due to overall low fungal abundance in sputum, we had a very small sample size. A more detailed description of the mycobiome results is included in the supplemental information.

Discussion

Distinction between sputum and saliva

The most abundant bacterial phyla in both sputum and saliva samples were Actinobacteria, Firmicutes, Bacteroidetes, and Proteobacteria. The major phyla identified in the sputum and saliva samples are consistent with those found in previous studies [50,79,80]. The Bray-Curtis dissimilarity measures also showed a distinction between the two sample types for bacteria.
The saliva and sputum samples clustered closely, but there was still a noticeable distinction between the two. The Bray-Curtis and Jaccard NMDS plots showed separation between sample type, but the UniFrac NMDS plot did not show separation between sample type. This suggests that while the abundance and presence/absence measures show separation between sample type, sputum and saliva do not appear to be different when considering the phylogenetic distances. These results are consistent with the alpha diversity analyses, where there was a significant difference between sample type in Shannon diversity and number of observed ASVs, but not phylogenetic diversity. The alpha and beta diversity results make sense when considering that while the growth conditions in the lungs and the oral cavity are quite different, the migration of microbes into the airways occurs primarily through microaspiration of saliva [2]. Additionally, the differences in alpha diversity and beta diversity between sample type indicate that the sputum was not entirely contaminated by the oral microbiome.

**Bacteriome differences in TRAP exposure groups**

As previous studies have shown that asthmatics tend to have greater alpha diversity in their respiratory tracts than non-asthmatics, and exposure to TRAP is associated with a higher incidence of asthma, asthma status was examined as a potential confounder [39]. We compared the diversity indices between asthmatics and non-asthmatics. While the mean number of observed ASVs, Shannon diversity, and phylogenetic diversity were slightly higher in asthmatics than in non-asthmatics, the confidence intervals of asthmatics and non-asthmatics overlapped in each alpha diversity measure. In contrast, the confidence intervals of the high and low TRAP-exposure groups did not overlap in the mean number of ASVs nor the mean phylogenetic diversity. These results are consistent with the Wilcoxon rank sum test p-values and the diversity measure box plots. Thus, asthma status does not appear to have a significant impact on our results of overall diversity comparisons between high and low TRAP exposure groups. However, as there were far fewer asthmatics than non-asthmatics included in the study, it is difficult to make a clear determination of differences in relative abundance between the asthma status groups. We also observed greater alpha diversity indices in the sputum of females than in males. To our knowledge, there have been no previous studies that have documented a significant difference in the bacterial diversity of the lower respiratory tract between genders in asthmatic subjects [6], although a few studies showed respiratory bacterial microbiota and individual bacterial variability in lung cancer, bronchiectasis, and cystic fibrosis patients [81,82]. There have been studies of the gut and skin microbiome that have documented differences in the microbial communities between genders, with higher levels of specific taxa found in the gut of males, and overall higher bacterial diversity found on the skin of males [83,84]. In contrast to sputum, we did not observe any significant differences in the alpha diversity indices of saliva between TRAP exposure groups, gender, or asthma status groups. This further supports the notion that the bacterial microbiome in the sputum samples is distinct from that in the saliva samples.

The results of the multiple regression model were consistent with the results of the univariate analysis (Table 2). Neither asthma status nor mother’s education were significant predictors of alpha diversity indices, further supporting that asthma status did not have a significant impact on our results of the TRAP exposure group comparisons. The results of the regression model with TRAP as a categorical variable are consistent with the Wilcoxon rank sum test results comparing diversity indices between exposure groups. The results of the regression model with TRAP as a continuous variable (ECAT) further strengthen the notion that TRAP exposure increases bacterial diversity in the lower respiratory tract. The models for phylogenetic diversity had the highest $R^2$ values, and the models for Shannon diversity had the lowest
values. It should be noted that we cannot rule out that unmeasured confounders or model misspecification resulted in residual bias in our estimates.

TRAP exposure affects the body in several ways that may be impacting the bacterial diversity in the lower respiratory tract. The bacterial communities in the airways are believed to originate primarily from microaspiration of saliva and are maintained through defense mechanisms, including mucociliary clearance and immune responses [50]. There is evidence that exposure to NO\textsubscript{2}, a component of TRAP, impairs mucociliary activity, which would increase the number of microbes that remain in the airways [85,86]. Additionally, the PM component of TRAP has been shown to increase the adhesion of bacteria to human airway epithelial cells [26], promote an airway inflammatory response [22–25], and reduce the production of antimicrobial peptides [37]. It is unclear which of these mechanisms contributes to the increase in diversity and should be an area of focus in future research.

Lower bacterial diversity is usually associated with diseased states in parts of the body, such as the gut [87–89]. In contrast, in the lungs, some diseases, such as asthma, are associated with greater bacterial diversity [39]. It is well-understood in microbial ecology that a diverse population protects against biological invasions and is able to use resources more efficiently [90–92]. Biodiversity acts as insurance to maintain a functioning ecosystem under abiotic perturbations and anthropogenic disturbances [93]. As TRAP has been shown to increase the adhesion of bacteria to respiratory tract epithelial cells, it is possible that the alteration in growth conditions in the TRAP-exposed respiratory tract could promote the development of a more diverse bacterial community. Additionally, this change in microbial communities may elicit a local immune response, or even impact immune system development in children. Future studies should examine the relationship between TRAP-induced changes in bacterial diversity in the lungs and respiratory health.

There was not a significant difference in beta diversity between the TRAP exposure groups. This indicates that while alpha diversity in sputum is associated with traffic pollution exposure within the range of observed values, the microbial composition between the high and low exposure groups is not significantly different. The relative abundance of bacterial phyla in sputum also did not appear to differ between TRAP exposure group or gender, but asthmatics appeared to have more Bacteroidetes and fewer Proteobacteria. Inconsistent with our results, previous studies have documented higher levels of Proteobacteria in asthmatics compared to non-asthmatics [28,39]. Additionally, the overall bacterial load was significantly greater in asthmatic than non-asthmatic participants. This result is consistent with previous research that has shown higher bacterial loads in asthmatics [40]. However, it should be noted that we had fewer non-asthmatic than asthmatic participants included in this study.

While the overall microbial community composition did not appear to differ between TRAP exposure groups, negative binomial regression was able to identify several differentially abundant individual ASVs between TRAP exposure groups, including Fusobacterium nucleatum and one ASV in the genus Atopobium. ASVs in Prevotella did not have a statistically significant FDR p-value, but consistently had >2 log2 fold-changes. Fusobacterium is associated with several human diseases, most commonly periodontal and oropharyngeal infections, produces a potent endotoxin, and is known to assist in the development of biofilms [94–96]. Biofilms are known to form in the lungs of cystic fibrosis patients, so it is possible that the biofilm property of Fusobacterium may be relevant to respiratory health [97]. Atopobium is associated with bacterial vaginosis [98]. Prevotella is associated with anaerobic lower respiratory tract infections [99]. While we cannot meaningfully remark on the biological significance of these findings, these may be taxa of interest in future investigations regarding TRAP exposure and the respiratory microbiome. We also identified differentially abundant ASVs across gender and asthma status. Across gender, there were two differentially abundant ASVs in
Fusobacterium, one ASV in Campylobacter, and one ASV in Prevotella. A study on the gut microbiome also identified higher levels of Prevotella in males than in females [83]. Across asthma status, there was one differentially abundant ASV identified as *Prevotella salivae*, and one ASV in Bacillus. It has been proposed that a higher abundance of *Prevotella* in the lungs may increase airway inflammation [100].

Traffic pollution and the respiratory mycobiome

Our pilot study results did not indicate a difference between the mycobiomes of sputum in the high and low TRAP-exposed participants. This could be because we had a small sample size and the samples that did amplify had very low abundance. Additionally, fungi do not proliferate to the same extent as bacteria in the lower respiratory tract. In contrast to bacteria, we were unable to conduct a linear regression for fungi due to the small sample size. Further discussion of the mycobiome results are included in the supplemental information.

Strengths and limitations

A major strength of this study is the well-characterized TRAP exposure history of the CCAAPS cohort. While ECAT as a TRAP marker is unique to the CCAAPS cohort, we have reported multiple health outcomes associated with increased exposure to this marker, including childhood wheeze, asthma onset, anxiety, and depression [58,101,102]. The concentrations of this pollutant are not directly comparable to other TRAP surrogates, including NO2, and therefore there is no general guideline on what ‘high’ or ‘low’ concentrations of ECAT are. However, a key strength is the quantitative estimate of this marker for all CCAAPS participants applied to locations throughout their childhood which provides a gradient of exposures for the study population enabling our analyses. Using ECAT we were able to show the effect of TRAP exposure on bacterial diversity in the lower respiratory tract as both a categorical and continuous variable. Additionally, while the data support that asthma status did not significantly impact our bacterial results, it must be noted that we had very few asthmatics compared to non-asthmatics in this study. We also did not have the specific endotypes of the asthmatic participants. Previous studies have shown that specific asthma endotypes may impact the respiratory microbiome in different ways [50].

Another strength of this study is that we conducted both 16s and ITS metagenomic sequencing and qPCR with universal bacterial and fungal primers on all samples. Therefore, we were able to normalize our sequencing results with the qPCR data instead of relying on statistical methods, such as rarefaction, to account for sequencing depth. One limitation of the qPCR method is that for both bacteria and fungi, species contain variable numbers of the amplified genomic region [63]. Therefore, the measurement of the total number of bacterial and fungal genome copies per mL of sputum may be affected by the species present in the sample.

We selected the induced sputum method over bronchoalveolar lavage because it is less invasive. Therefore, oral contamination of the sputum samples was a major concern in this study. However, one strength of this study is that our results demonstrated that the saliva and sputum samples had distinct bacterial communities, indicating that the sputum samples were not entirely contaminated by the oral microbiome. It should also be noted that the lungs have a wide range of microgeographic conditions, with a temperature gradient from ambient air temperature to body temperature in the short distance from the point of inhalation to the alveoli, so future studies may want to focus on specific locations within the lower respiratory tract.

Conclusions

These findings indicate that exposure to TRAP in early childhood and adolescence is associated with greater bacterial diversity in the lower respiratory tract in our sample of participants.
It is still unknown whether the development of asthma changes the lower respiratory tract microbiome or if an altered microbiome mediates a change in disease status. However, these results demonstrate that there may be a TRAP-exposure-related change in the lower-respiratory microbiome that is independent of asthma status. We also identified several taxa of interest for future studies, including *Fusobacterium*, *Atopobium*, and *Prevotella*. A major limitation of this study was the small sample size, so a larger pool of participants is needed to confirm our findings. Additionally, a study with a larger sample size could use model-based approaches for a more robust examination of the relationship of TRAP exposure and the respiratory microbiome. Further research characterizing the human microbiome in relation to environmental exposures can lead to important new discoveries into how the body is impacted by these exposures.

**Supporting information**

**S1 Fig.** Bar plots showing the relative abundance of each bacterial phyla in sputum and saliva.

(DOCX)

**S2 Fig.** NMDS (upper graphs) and MDS (lower graphs) plots using Bray-Curtis, unweighted UniFrac, and Jaccard beta diversity measurements to compare the bacteriomes in sputum and saliva.

(DOCX)

**S3 Fig.** Box plots comparing bacterial diversity indices in sputum between (A) asthma status and (B) gender, including Shannon diversity, number of observed amplicon sequence variants (ASVs), and Faith’s phylogenetic diversity.

(DOCX)

**S4 Fig.** Box plots comparing bacterial diversity indices in saliva between (A) TRAP exposure groups, (B) asthma status groups, and (C) gender, including Shannon diversity, number of observed amplicon sequence variants (ASVs), and Faith’s phylogenetic diversity.

(DOCX)

**S5 Fig.** Bar plots showing the relative abundance of bacterial phyla in sputum across TRAP exposure groups, asthma status groups, and genders.

(DOCX)

**S6 Fig.** DESeq2 results showing the log2 fold-change values (x-axis) in sputum bacteriome between genders. Each line on the y-axis indicates the family, each point represents an individual ASV within that family, and the color of the point indicates the phylum.

(DOCX)

**S7 Fig.** DESeq2 results showing the log2 fold-change values (x-axis) in sputum bacteriome between asthma status groups. Each line on the y-axis indicates the family, each point represents an individual ASV within that family, and the color of the point indicates the phylum.

(DOCX)

**S1 Table.** Mean (95% confidence interval) and Wilcoxon rank sum test p-value for each fungal alpha diversity measure in the sputum by TRAP exposure, asthma status, and gender.

(DOCX)

**S1 File.** Supplemental info–mycobiome.

(DOCX)
Acknowledgments

We thank Reshmi Indugula, who assisted with the qPCR analyses.

Author Contributions

Conceptualization: Patrick H. Ryan, Atin Adhikari, Tiina Reponen.

Formal analysis: Christine Niemeier-Walsh.

Funding acquisition: Atin Adhikari, Tiina Reponen.

Investigation: Christine Niemeier-Walsh, Tiina Reponen.

Methodology: Christine Niemeier-Walsh, Patrick H. Ryan, Jaroslaw Meller, Nicholas J. Ollberding, Atin Adhikari.

Project administration: Tiina Reponen.

Resources: Patrick H. Ryan.

Software: Jaroslaw Meller, Nicholas J. Ollberding.

Supervision: Tiina Reponen.

Validation: Christine Niemeier-Walsh, Jaroslaw Meller.

Visualization: Christine Niemeier-Walsh.

Writing – original draft: Christine Niemeier-Walsh.

Writing – review & editing: Patrick H. Ryan, Jaroslaw Meller, Nicholas J. Ollberding, Atin Adhikari, Tiina Reponen.

References

1. Dickson RP, Huffnagle GB. The Lung Microbiome: New Principles for Respiratory Bacteriology in Health and Disease. PLoS Pathog. 2015; 11(7):e1004923. https://doi.org/10.1371/journal.ppat.1004923 PMID: 26158874

2. Bassis CM, Erb-Downward JR, Dickson RP, Freeman CM, Schmidt TM, Young VB, et al. Analysis of the upper respiratory tract microbiota as the source of the lung and gastric microbiotas in healthy individuals. MBio. 2015; 6(2):e00037–15. https://doi.org/10.1128/mBio.00037-15 PMID: 25736890

3. Charlson ES, Bittinger K, Chen J, Diamond JM, Li H, Collman RG, et al. Assessing bacterial populations in the lung by replicate analysis of samples from the upper and lower respiratory tracts. PloS One. 2012; 7(9):e42786. https://doi.org/10.1371/journal.pone.0042786 PMID: 22970118

4. Charlson ES, Bittinger K, Haas AR, Fitzgerald AS, Frank I, Yadav A, et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. American Journal of Respiratory and Critical Care Medicine. 2011; 184(8):957–63. https://doi.org/10.1164/rccm.201104-0655OC PMID: 21680950

5. Morris A, Beck JM, Schlose PD, Campbell TB, Crothers K, Curtis JL, et al. Comparison of the respiratory microbiome in healthy nonsmokers and smokers. American Journal of Respiratory and Critical Care Medicine. 2013; 187(10):1067–75. https://doi.org/10.1164/rccm.201210-1913OC PMID: 23491408

6. Pragman AA, Kim HB, Reilly CS, Wendt C, Isaacson RE. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PloS One. 2012; 7(10):e47305. https://doi.org/10.1371/journal.pone.0047305 PMID: 23071781

7. Gallacher D, Alber D, Logan G, Klein N, Marchesi J, Kotecha S. Early life lung microbiome in preterm infants. European Respiratory Journal. 2018; 52(suppl 62):PA4657.

8. Dickson RP, Martinez FJ, Huffnagle GB. The role of the microbiome in exacerbations of chronic lung diseases. The Lancet. 2014; 384(9944):691–702. https://doi.org/10.1016/S0140-6736(14)61136-3 PMID: 25152271
9. Brunekreef B, Janssen NA, de Hartog J, Harssema H, Knape M, van Vliet P. Air pollution from truck traffic and lung function in children living near motorways. Epidemiology. 1997;298–303. https://doi.org/10.1097/00001648-199705000-00012 PMID: 9115026

10. Ciccone G, Forastiere F, Agabiti N, Biggeri A, Bisanti L, Chellini E, et al. Road traffic and adverse respiratory effects in children. SIDRIA Collaborative Group. Occupational and Environmental Medicine. 1998; 55(11):771–8. https://doi.org/10.1136/oem.55.11.771 PMID: 9924455

11. Edwards J, Walters S, Griffiths RK. Hospital admissions for asthma in preschool children: relationship to major roads in Birmingham, United Kingdom. Archives of Environmental Health: An International Journal. 1994; 49(4):223–7.

12. Gauderman WJ, Avol E, Gilliland F, Vora H, Thomas D, Berhane K, et al. The effect of air pollution on lung development from 10 to 18 years of age. New England Journal of Medicine. 2004; 351(11):1057–67. https://doi.org/10.1056/NEJMoa040610 PMID: 15356303

13. McConnell R, Berhane K, Yao L, Jerrett M, Lurmann F, Gilliland F, et al. Traffic, susceptibility, and childhood asthma. Environmental Health Perspectives. 2006:766–72. https://doi.org/10.1289/ehp.8594 PMID: 16675435

14. Migliaretti G, Cavallo F. Urban air pollution and asthma in children. Pediatric Pulmonology. 2004; 38(3):198–203. https://doi.org/10.1002/ppul.20057 PMID: 15274097

15. Nitta H, Sato T, Nakai S, Maeda K, Aoki S, Ono M. Respiratory health associated with exposure to automobile exhaust. I. Results of cross-sectional studies in 1979, 1982, and 1983. Archives of Environmental Health: An International Journal. 1993; 48(1):53–8.

16. Oosterlee A, Drijver M, Lebret E, Brunekreef B. Chronic respiratory symptoms in children and adults living along streets with high traffic density. Occupational and Environmental Medicine. 1996; 53(4):241–7. https://doi.org/10.1136/oem.53.4.241 PMID: 8664961

17. Van Vliet P, Knape M, de Hartog J, Janssen N, Harssema H, Brunekreef B. Motor vehicle exhaust and chronic respiratory symptoms in children living near freeways. Environmental Research. 1997; 74(2):122–32. https://doi.org/10.1136/enns.1997.3757 PMID: 9339225

18. Wjst M, Reitmeir P, Dold S, Wulf A, Nicolai T, von Loefelfholz-Colberg EF, et al. Road traffic and adverse effects on respiratory health in children. Bmj; 1993; 307(6904):596–600. https://doi.org/10.1136/bmj.307.6904.596 PMID: 7691304

19. Zmirou D, Gauvin S, Pin I, Momas I, Sahraoui F, Just J, et al. Traffic related air pollution and incidence of childhood asthma: results of the Vesta case-control study. Journal of Epidemiology and Community Health. 2004; 58(1):18–23. https://doi.org/10.1136/jech.58.1.18 PMID: 14684722

20. Medina-Ramón M, Zanobetti A, Schwartz J. The effect of ozone and PM10 on hospital admissions for pneumonia and chronic obstructive pulmonary disease: a national multicity study. American Journal of Epidemiology. 2006; 163(6):579–88. https://doi.org/10.1093/aje/kwj078 PMID: 16443803

21. Neupane B, Jerrett M, Burnett RT, Marrie T, Arain A, Loeb M. Long-term exposure to ambient air pollution and risk of hospitalization with community-acquired pneumonia in older adults. American Journal of Respiratory and Critical Care Medicine. 2010; 181(1):47–53. https://doi.org/10.1164/rccm.200901-0160OC PMID: 19797763

22. Bunn H, Dinsdale D, Smith T, Grigg J. Ultrafine particles in alveolar macrophages from normal children. Thorax. 2001; 56(12):932–4. https://doi.org/10.1136/thorax.56.12.932 PMID: 11713355

23. Kocbach A, Johansen B, Schwarzpe P, Namork E. Analytical electron microscopy of combustion particles: a comparison of vehicle exhaust and residential wood smoke. Science of the Total Environment. 2005; 346(1):231–43. https://doi.org/10.1016/j.scitotenv.2004.10.025 PMID: 15993697

24. Donaldson K, Stone V, Borm PJ, Jimenez LA, Gilmour PS, Schins RP, et al. Oxidative stress and calcium signaling in the adverse effects of environmental particles (PM 10). Free Radical Biology and Medicine. 2003; 34(11):1369–82. https://doi.org/10.1016/s0891-5849(03)00150-3 PMID: 12757847

25. Calcabrini A, Meschini S, Marra M, Falzano L, Colone M, De Berardis B, et al. Fine environmental particulate engenders alterations in human lung epithelial A549 cells. Environmental Research. 2004; 95(1):82–91. https://doi.org/10.1016/j.envres.2003.07.011 PMID: 15068934

26. Mushqat N, Ezzati M, Hall L, Dickson I, Kinwan M, Png KM, et al. Adhesion of Streptococcus pneumoniae to human airway epithelial cells exposed to urban particulate matter. Journal of Allergy and Clinical Immunology. 2011; 127(5):1236–42. e2. https://doi.org/10.1016/j.jaci.2010.11.039 PMID: 21247619

27. Huffnagle GB. The microbiota and allergies/asthma. PLoS Pathog. 2010; 6(5):e1000549. https://doi.org/10.1371/journal.ppat.1000549 PMID: 20523892

28. Hilly M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C, et al. Disordered microbial communities in asthmatic airways. PLoS One. 2010; 5(1):e8578. https://doi.org/10.1371/journal.pone.0008578 PMID: 20052417
29. Bisgaard H, Hermansen MN, Buchvald F, Loland L, Halkjaer LB, Børnelykke K, et al. Childhood asthma after bacterial colonization of the airway in neonates. New England Journal of Medicine. 2007; 357(15):1487–95. https://doi.org/10.1056/NEJMoa052632 PMID: 17928596

30. Eder W, Ege MJ, von Mutius E. The asthma epidemic. New England Journal of Medicine. 2006; 355(21):2226–35. https://doi.org/10.1056/NEJMra054308 PMID: 17124020

31. Suzaki H, Watanabe S, Pawankar R. Rhinosinusitis and asthma-microbiome and new perspectives. Current Opinion in Allergy and Clinical Immunology. 2013; 13(1):45–9. https://doi.org/10.1097/ACI.0b013e32835b34f6 PMID: 23128418

32. Ege M, Mayer M, Schwaiger K, Mattes J, Pershagen G, Van Hage M, et al. Environmental bacteria and childhood asthma. Allergy. 2012; 67(12):1565–71. https://doi.org/10.1111/all.12026 PMID: 22994424

33. Cohen AJ RAH, Ostro B, Pandey KD, Krzyzanowski M, KüNZli N, Gutschmidt K, et al. Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors. Ezzati M LA, Rodgers A, Murray CL, editor. Geneva: World Health Organization; 2004.

34. Donaldson K, Tran L, Jimenez LA, Duffin R, Newby DE, Mills N, et al. Combustion-derived nanoparticles: a review of their toxicology following inhalation exposure. Particle and Fibre Toxicology. 2005; 2(1):10. https://doi.org/10.1186/1743-8977-2-10 PMID: 16242040

35. Ibald-Mulli A, Wichmann HE, Kreyling W, Peters A. Epidemiological evidence on health effects of ultrafine particles. Journal of Aerosol Medicine: the official journal of the International Society for Aerosols in Medicine. 2002; 15(2):189–201. https://doi.org/10.1089/08942680232028310 PMID: 12184869

36. Laden F, Neas LM, Dockery DW, Schwartz J. Association of fine particulate matter from different sources with daily mortality in six U.S. cities. Environ Health Perspect. 2000; 108(10):941–7. https://doi.org/10.1289/ehp.00108941 PMID: 11049813

37. Chen X, Liu J, Zhou J, Wang J, Chen C, Song Y, et al. Urban particulate matter (PM) suppresses airway antibacterial defence. Respiratory Research. 2018; 19(1):5. https://doi.org/10.1186/s12931-017-0700-0 PMID: 29310642

38. Barnett AG, Williams GM, Schwartz J, Neller AH, Best TL, Petroeschovsky AL, et al. Air pollution and child respiratory health: a case-crossover study in Australia and New Zealand. American Journal of Respiratory and Critical Care Medicine. 2005; 171(11):1272–8. https://doi.org/10.1164/rccm.200411-1586OC PMID: 15764722

39. Marri PR, Stern DA, Wright AL, Billheimer D, Martinez FD. Asthma-associated differences in microbial composition of induced sputum. Journal of Allergy and Clinical Immunology. 2013; 131(2):346–52. e3. https://doi.org/10.1016/j.jaci.2012.11.013 PMID: 23265859

40. Huang YJ, Nelson CE, Brodie EL, DeSantis TZ, Baek MS, Liu J, et al. Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. Journal of Allergy and Clinical Immunology. 2011; 127(2):372–81. e3. https://doi.org/10.1016/j.jaci.2010.10.048 PMID: 21194740

41. Mao Q, Jiang F, Yin R, Wang J, Xia W, Dong G, et al. Interplay between the lung microbiome and lung cancer. Cancer Letters. 2018; 415:40–8. https://doi.org/10.1016/j.canlet.2017.11.036 PMID: 29197615

42. Salim SY, Kaplan GG, Madsen KL. Air pollution effects on the gut microbiota: a link between exposure and inflammatory disease. Gut Microbes. 2014; 5(2):215–9. https://doi.org/10.4161/gmic.27251 PMID: 24637593

43. Qu J, Li Y, Zhong W, Gao P, Hu C. Recent developments in the role of reactive oxygen species in allergic asthma. Journal of Thoracic Disease. 2017; 9(1):E32. https://doi.org/10.21037/jtd.2017.01.05 PMID: 28203435

44. Alderete TL, Jones RB, Chen Z, Kim JS, Habre R, Lurmann F, et al. Exposure to traffic-related air pollution and the composition of the gut microbiota in overweight and obese adolescents. Environmental Research. 2018; 161:472–8. https://doi.org/10.1016/j.envres.2017.11.046 PMID: 29220800

45. Ribière C, Peyret P, Parisot N, Darcha C, Déchelotte PJ, Barnich N, et al. Oral exposure to environmental pollutant benzo [a] pyrene impacts the intestinal epithelium and induces gut microbial shifts in murine model. Scientific Reports. 2016; 6:31027. https://doi.org/10.1038/srep31027 PMID: 27753127

46. Beamish LA, Osorno-Vargas AR, Wine E. Air pollution: An environmental factor contributing to intestinal disease. Journal of Crohn’s and Colitis. 2011; 5(4):279–86. https://doi.org/10.1016/j.jcrohns.2011.02.017 PMID: 21683297

47. Kish L, Hotte N, Kaplan GG, Vincent R, Tso R, Gänzle M, et al. Environmental particulate matter induces murine intestinal inflammatory responses and alters the gut microbiome. PloS One. 2013; 8(4):e62220. https://doi.org/10.1371/journal.pone.0062220 PMID: 23638009
48. Adar SD, Huffnagle GB, Curtis JL. The respiratory microbiome: an underappreciated player in the human response to inhaled pollutants? Annals of Epidemiology. 2016; 26(5):355–9. https://doi.org/10.1016/j.annepidem.2016.03.010 PMID: 27161078

49. Mestecky J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. Journal of Clinical Immunology. 1987; 7(4):265–76. https://doi.org/10.1007/BF00915547 PMID: 3301884

50. Wypych TP, Wickramasinghe LC, Marsland BJ. The influence of the microbiome on respiratory health. Nature Immunology. 2019;1–12. https://doi.org/10.1038/s41590-019-0451-9 PMID: 31501577

51. Ryan PH, LeMasters G, Biagini J, Bernstein D, Grinshpun SA, Shukla R, et al. Is it traffic type, volume, or distance? Wheezing in infants living near truck and bus traffic. Journal of Allergy and Clinical Immunology. 2005; 116(2):279–84. https://doi.org/10.1016/j.jaci.2005.05.014 PMID: 16083780

52. Cho S-H, Reponen T, LeMasters G, Levin L, Huang J, Meklin T, et al. Mold damage in homes and wheezing in infants. Annals of Allergy, Asthma & Immunology. 2006; 97(4):539–45. https://doi.org/10.1016/S1018-1206(10)60947-7 PMID: 17069111

53. Iossifova YY, Reponen T, Ryan PH, Levin L, Bernstein DI, Lockey JE, et al. Mold exposure during infancy as a predictor of potential asthma development. Annals of Allergy, Asthma & Immunology. 2009; 102(2):131–7. https://doi.org/10.1016/S1081-1206(10)60243-8 PMID: 19230464

54. LeMasters GK, Wilson K, Levin L, Biagini J, Ryan P, Lockey JE, et al. High prevalence of aeroallergen sensitization among infants of atopic parents. The Journal of Pediatrics. 2006; 149(4):505–11. https://doi.org/10.1016/j.jpeds.2006.06.035 PMID: 17011322

55. Reponen T, Lockey J, Bernstein DI, Vesper SJ, Levin L, Hershey GKK, et al. Infant origins of childhood asthma associated with specific molds. Journal of Allergy and Clinical Immunology. 2012; 130(3):639–44. e5. https://doi.org/10.1016/j.jaci.2012.05.030 PMID: 22789397

56. Reponen T, Vesper S, Levin L, Johansson E, Ryan P, Burkle J, et al. High environmental relative moldiness index during infancy as a predictor of asthma at 7 years of age. Annals of Allergy, Asthma & Immunology. 2011; 107(2):120–6. https://doi.org/10.1016/j.anai.2011.04.018 PMID: 21802019

57. Tunney MM, Einarsson GG, Wei L, Drain M, Klem ER, Cardwell C, et al. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. American Journal of Respiratory and Critical Care Medicine. 2013; 187(10):1118–26. https://doi.org/10.1164/rccm.201210-1937OC PMID: 23348972

58. Ryan PH, LeMasters GK, Biswas P, Levin L, Hu S, Lindsey M, et al. A comparison of proximity and land use regression traffic exposure models and wheezing in infants. Environmental Health Perspectives. 2007;278–84. https://doi.org/10.1289/ehp.9480 PMID: 17384778

59. Ryan PH, LeMasters GK, Levin L, Burkle J, Biswas P, Hu S, et al. A land-use regression model for estimating microenvironmental diesel exposure given multiple addresses from birth through childhood. Science of the Total Environment. 2008; 404(1):139–47. https://doi.org/10.1016/j.scitotenv.2008.05.051 PMID: 18625514

60. Hu S, McDonald R, Martuzevicius D, Biswas P, Grinshpun SA, Kelley A, et al. UNMIX modeling of ambient PM 2.5 near an interstate highway in Cincinnati, OH, USA. Atmospheric Environment. 2006; 40:378–95. https://doi.org/10.1016/j.atmosenv.2006.02.038 PMID: 21720518

61. Sahu M, Hu S, Ryan PH, LeMasters G, Grinshpun SA, Chow JC, et al. Chemical compositions and source identification of PM 2.5 aerosols for estimation of a diesel source surrogate. Science of the Total Environment. 2011; 409(13):2642–51.

62. Luhung I, Wu Y, Ng CK, Miller D, Cao B, Chang VW-C. Protocol improvements for low concentration DNA-based bioaerosol sampling and analysis. PloS One. 2015; 10(11):e0141158. https://doi.org/10.1371/journal.pone.0141158 PMID: 26619279

63. Nadkarni MA, Martin FE, Jacques NA, Hunter N. Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. Microbiology. 2002; 148(1):257–66. https://doi.org/10.1099/00221287-148-1-257 PMID: 11782518

64. Haugland R, Vesper S, InventorsMethod of identifying and quantifying specific fungi and bacteria. US Patent US8387652B12002.

65. Manley LJ, Ma D, Levine SS. Monitoring Error Rates In Illumina Sequencing. Journal of biomolecular techniques: JBT. 2016; 27(4):125–8. https://doi.org/10.7171/jbt.16-2704-002 PMID: 27672352

66. Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. Applied and Environmental Microbiology. 2013; 79(17):5112–20. https://doi.org/10.1128/AEM.01043-13 PMID: 23793624

67. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBO Journal. 2011; 17(1):10–12.
68. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2: high-resolution sample inference from Illumina amplicon data. Nature Methods. 2016; 13(7):581. https://doi.org/10.1038/nmeth.3868 PMID: 27214047

69. Callahan B. Silva taxonomic training data formatted for DADA2 (Silva version 132). Zenodo. 2018.

70. Wright ES. Using DECIPHER v2.0 to analyze big biological sequence data in R. R Journal. 2016; 8(1):1–8.

71. Schliep KP, phangorn: phylogenetic analysis in R. Bioinformatics. 2010; 27(4):592–3. https://doi.org/10.1093/bioinformatics/btp706 PMID: 21169378

72. McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PloS One. 2013; 8(4):e61217. https://doi.org/10.1371/journal.pone.0061217 PMID: 23630581

73. Callahan BJ, McMurdie PJ, Holmes SP. Exact sequence variants should replace operational taxonomic units in marker-gene data analysis. The ISME Journal. 2017; 11(12):2639. https://doi.org/10.1038/ismej.2017.119 PMID: 28731476

74. Jian C, Luukkonen P, Yki-Jarvinen H, Salonen A, Korpela K. Quantitative PCR provides a simple and accessible method for quantitative microbiome profiling. bioRxiv. 2018:478685.

75. Dannemiller KC, Lang-Yona N, Yamamoto N, Rudich Y, Peccia J. Combining real-time PCR and next-generation DNA sequencing to provide quantitative comparisons of fungal aerosol populations. Atmospheric Environment. 2014; 84:113–21.

76. Kembel SW, Cowan PD, Helmus MR, Cornwell WK, Morlon H, Ackerly DD, et al. Picante: R tools for integrating phylogenies and ecology. Bioinformatics. 2010; 26(11):1463–4. https://doi.org/10.1093/bioinformatics/btq166 PMID: 20395285

77. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biology. 2014; 15(12):550. https://doi.org/10.1186/s13059-014-0550-8 PMID: 25516281

78. La Rosa PS, Brooks JP, Deych E, Boone EL, Edwards DJ, Wang Q, et al. Hypothesis testing and power calculations for taxonomic-based human microbiome data. PloS One. 2012; 7(12):e52078. https://doi.org/10.1371/journal.pone.0052078 PMID: 23284876

79. Dickson RP, Erb-Downward JR, Huffnagle GB. The role of the bacterial microbiome in lung disease. Expert Review of Respiratory Medicine. 2013; 7(3):245–57. https://doi.org/10.1586/ers.13.24 PMID: 23734647

80. Bacci G, Taccetti G, Dolce D, Armanini F, Segata N, Di Cesare F, et al. Untargeted Metagenomic Investigation of the Airway Microbiome of Cystic Fibrosis Patients with Moderate-Severe Lung Disease. Microorganisms. 2020; 8(7):1003. https://doi.org/10.3390/microorganisms8071003 PMID: 32635564

81. Mueller S, Saunier K, Hanisch C, Norin E, Aim L, Midtvedt T, et al. Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study. Appl Environ Microbiol. 2006; 72(2):1027–33. https://doi.org/10.1128/AEM.72.2.1027-1033.2006 PMID: 16461645

82. Zeeuwen PL, Boekhorst J, van den Bogaard EH, de Koning HD, van de Kerkhof PM, Saulnier DM, et al. Microbiome dynamics of human epidermis following skin barrier disruption. Genome Biology. 2012; 13(11):R101. https://doi.org/10.1186/gb-2012-13-11-r101 PMID: 23153041

83. Brant T, Yoshida CT, Carvalho TD, Nicola ML, Martins JA, Braga LM, et al. Mucociliary clearance, airway inflammation and nasal symptoms in urban motorcyclists. Clinics. 2014; 69(12):867–70. https://doi.org/10.6061/clinics/2014(12)13 PMID: 25628001

84. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nature Reviews Genetics. 2012; 13(4):260–70. https://doi.org/10.1038/nrg3182 PMID: 22411464
